Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fuss Brands Corp (FBDS)
New York, NY, US
Fuss Brands Corp. does not have significant operations. It intends to explore and identify business opportunities within the United States, including a potential acquisition of an operating entity through a reverse merger, asset purchase, or similar transaction. The company was formerly known as China Botanic Pharmaceutical Inc. and changed its name to Fuss Brands Corp. in July 2022. Fuss Brands Corp. was incorporated in 1988 and is based in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +81.65% | +80.36% | +124.44% | -17.55% | -95.14% | +1,842.31% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%-353.1% Q3'25: +58.3% (vs Q3'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%— Q3'25: +10.0% (vs Q3'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+16.7% Q3'25: +12.4% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×— Q3'25: 0.00× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2011 | Weiqiu Dong, Chief Financial Officer | 92.0K | — | — | 259.3K | — | — | 3.51M | 7.38% | ↗ |
| 2 | 2011 | Shaoming Li, Chairman of Board of Directors, Chief Executive Officer, and President | 31.3K | — | — | — | — | — | 31.3K | 0.00% | ↗ |
| 3 | 2011 | Xiaoying Lu, Former Interim Chief Financial Officer | 7.1K | — | — | — | — | — | 7.1K | 0.00% | ↗ |
| 4 | 2011 | Jiang He, Secretary | 4.5K | — | — | — | — | — | 4.5K | 0.00% | ↗ |
| 5 | 2010 | Yan Yi Chen, Former Interim Chief Financial Officer | 33.6K | — | — | — | — | — | 32.2K | 0.00% | ↗ |
| 6 | 2010 | Shaoming Li, Chairman of Board of Directors, Chief Executive Officer, and President | 31.3K | — | — | — | — | — | 31.3K | 0.00% | ↗ |
| 7 | 2010 | Xiaoying Lu, Former Interim Chief Financial Officer | 7.1K | — | — | — | — | — | 7.1K | 0.00% | ↗ |
| 8 | 2010 | Jiang He, Secretary | 4.5K | — | — | — | — | — | 4.5K | 0.00% | ↗ |
| 9 | 2010 | Wang Zuoliang Former Interim Chief Financial Officer | 4.5K | — | — | — | — | — | 4.5K | 0.00% | ↗ |
| 10 | 2009 | Shaoming Li, Chairman of Board of Directors, Chief Executive Officer, and President | 31.3K | — | — | — | — | — | 31.3K | 0.00% | ↗ |
| 11 | 2009 | Xiaoying Lu, Former Interim Chief Financial Officer | 7.1K | — | — | — | — | — | 7.1K | 0.00% | ↗ |
| 12 | 2009 | Wang Zuoliang Former Interim Chief Financial Officer | 4.5K | — | — | — | — | — | 4.5K | 0.00% | ↗ |
| 13 | 2009 | Jiang He, Secretary | 4.5K | — | — | — | — | — | 4.5K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheskel Meisels | Chairman of the Board, Chief Financial Officer, Chief Executive Officer, Secretary & Treasurer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FBDS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
